104 related articles for article (PubMed ID: 22351989)
1. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice.
Nikolova I; Galabov AS
Antiviral Res; 2003 Sep; 60(1):35-40. PubMed ID: 14516919
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
Nikolaeva L; Galabov AS
Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of coxsackievirus type B1.
Abdelkhalek I; Seghier M; Yahia AB; Touzi H; Meddeb Z; Triki H; Rezig D
Arch Virol; 2015 Nov; 160(11):2815-21. PubMed ID: 26243282
[TBL] [Abstract][Full Text] [Related]
6. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus.
Nikolaeva-Glomb L; Galabov AS
Antiviral Res; 2004 Apr; 62(1):9-19. PubMed ID: 15026197
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication.
Nikolaeva L; Galabov AS
Acta Virol; 1995 Dec; 39(5-6):235-41. PubMed ID: 8722291
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of poliovirus uncoating by disoxaril (WIN 51711).
Zeichhardt H; Otto MJ; McKinlay MA; Willingmann P; Habermehl KO
Virology; 1987 Sep; 160(1):281-5. PubMed ID: 2820136
[TBL] [Abstract][Full Text] [Related]
9. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of the antigenicity of coxsackie B procapsids by disoxaril.
Frisk G; Halloran M; Didarholm H
J Virol Methods; 1993 Dec; 45(2):235-9. PubMed ID: 8113348
[TBL] [Abstract][Full Text] [Related]
11. Nucleotide sequence of the 5'nontranslated and virion polypeptides regions of coxsackievirus B6.
Kato S; Tsutsumi R; Sato S
Microbiol Immunol; 1999; 43(9):871-83. PubMed ID: 10553680
[TBL] [Abstract][Full Text] [Related]
12. A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes.
Stone VM; Hankaniemi MM; Svedin E; Sioofy-Khojine A; Oikarinen S; Hyöty H; Laitinen OH; Hytönen VP; Flodström-Tullberg M
Diabetologia; 2018 Feb; 61(2):476-481. PubMed ID: 29151123
[TBL] [Abstract][Full Text] [Related]
13. Molecular characteristics of human coxsackievirus B1 infection in Korea, 2008-2009.
Kim H; Kang B; Hwang S; Hong J; Chung J; Kim S; Jeong YS; Kim K; Cheon DS
J Med Virol; 2013 Jan; 85(1):110-5. PubMed ID: 23073968
[TBL] [Abstract][Full Text] [Related]
14. [Genomic characteristics of coxsackievirus B1 MSH/KM9/2009 strain isolated in Yunnan, China].
Liu JS; Shao CW; Pan Y; Zhu YJ; Deng XQ; Liao HW; Liu YL; Ma SH
Bing Du Xue Bao; 2013 May; 29(3):293-8. PubMed ID: 23905473
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
16. In vitro assembly of poliovirus 14 S subunits: disoxaril stabilization as a model for the antigenicity conferring activity of infected cell extracts.
Rombaut B; Boeyé A
Virology; 1991 Feb; 180(2):788-92. PubMed ID: 1703372
[TBL] [Abstract][Full Text] [Related]
17. Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril.
Jubelt B; Wilson AK; Ropka SL; Guidinger PL; McKinlay MA
J Infect Dis; 1989 May; 159(5):866-71. PubMed ID: 2540248
[TBL] [Abstract][Full Text] [Related]
18. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
20. Screening of a new candidate coxsackievirus B1 vaccine strain based on its biological characteristics.
Zhang M; Xu D; Liu Y; Wang X; Xu L; Gao N; Feng C; Guo W; Ma S
Front Microbiol; 2023; 14():1172349. PubMed ID: 37502400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
